Burón Andrea, Grau Jaume, Andreu Montserrat, Augé Josep M, Guayta-Escolies Rafael, Barau Mercè, Macià Francesc, Castells Antoni
Servicio de Epidemiología y Evaluación, Hospital del Mar, Barcelona, España; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Red de investigación en servicios de salud en enfermedades crónicas (REDISSEC), Barcelona, España.
Servicio de Medicina Preventiva y Epidemiologia, Hospital Clínic, Universitat de Barcelona, Barcelona, España.
Med Clin (Barc). 2015 Aug 21;145(4):141-6. doi: 10.1016/j.medcli.2014.05.027. Epub 2014 Jul 26.
The Colorectal Cancer Screening Program of Barcelona was implemented in December 2009 and involves pharmacies for the distribution and collection of screening tests. The aim of this article is to describe the main indicators of the first round of the Program (2010-2011), based on the ones suggested by the European Union.
The target population of the Colorectal Cancer Screening Program of Barcelona includes men and women aged 50-69 years who live in the catchment areas of Hospital Clínic and Hospital del Mar. Screening consists of biennial immunochemical fecal occult blood testing, with colonoscopy as confirmatory procedure.
Target population comprised 197,795 persons. Participation rate was 43.6%, was higher among women and among those aged 60 and older. 2.1% of the eligible population stated to have been already screened for colorectal cancer. Overall positivity rate was 6.2%, higher among men and with a broad variability among health care areas. The detection rates of low- and high-risk adenoma, and of invasive cancer were 9.1 ‰, 21.7 ‰ and 3.1 ‰, respectively. 48.2% of tumors were stage i.
These results are considered satisfactory and consistent with those obtained in other programs and with European standards. Nevertheless, some areas for improvement have been identified. The high participation rate can be attributed, at least in part, to the type of test and to the involvement of community pharmacies.
巴塞罗那结直肠癌筛查项目于2009年12月实施,该项目涉及通过药房分发和收集筛查检测。本文旨在根据欧盟建议的指标,描述该项目第一轮(2010 - 2011年)的主要指标。
巴塞罗那结直肠癌筛查项目的目标人群包括居住在Clínic医院和del Mar医院服务区域内年龄在50 - 69岁的男性和女性。筛查包括每两年进行一次免疫化学粪便潜血检测,并以结肠镜检查作为确诊程序。
目标人群为197,795人。参与率为43.6%,女性以及60岁及以上人群的参与率更高。2.1%的符合条件人群表示已接受过结直肠癌筛查。总体阳性率为6.2%,男性的阳性率更高,且各医疗区域之间存在较大差异。低风险和高风险腺瘤以及浸润性癌的检出率分别为9.1‰、21.7‰和3.1‰。48.2%的肿瘤为I期。
这些结果被认为是令人满意的,并且与其他项目以及欧洲标准所获得的结果一致。然而,已确定了一些需要改进的方面。高参与率至少部分可归因于检测类型以及社区药房的参与。